去(2-甲基丁酰)普伐他汀 | 151006-03-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 中文名称: 去(2-甲基丁酰)普伐他汀
• 中文别名: 普伐他汀杂质F
• 英文名称: DES(2-methylbutanoyl)pravastatin
• 英文别名: (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
• CAS: 151006-03-0
• 化学式: C₁₈H₂₈O₆
• 分子量: 340.4
• InChiKey: ZDADMCPDUNEBIX-CGDZNSRRSA-N

物化性质

• 沸点：
  636.9±55.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  118
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  去(2-甲基丁酰)普伐他汀 、 三乙胺 、 氰基磷酸二乙酯 在 四氢呋喃 、 乙醚 、 乙醇 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以to provide 47.7 g of the title compound的产率得到Pravastatin Diol Lactone
  参考文献：
  名称：

  Hexahydronaphthalene ester derivatives their preparation and their

  摘要：

  化合物的式子（I）：##STR1## 其中R.sup.1代表式子（II）或（III）的基团：##STR2## R.sup.2是烷基，烯基或炔基；R.sup.3和R.sup.4分别是氢，烷基，烯基或炔基；R.sup.5是氢或羧基保护基团；R.sup.a是式子--OR.sup.6的基团；R.sup.6是氢；R.sup.6a和R.sup.6b分别是氢，羟基保护基团，烷基，烷基磺酰，卤代烷基磺酰或芳基磺酰，以及它们的盐和酯。这些化合物抑制胆固醇的合成，可用于治疗和预防高胆固醇血症和各种心脏疾病。

  公开号：

  US05827855A1

文献信息

• Hexahydronaphthalene ester derivatives, their preparation and their
  申请人：Sankyo Company, Limited

  公开号：US05451688A1

  公开（公告）日：1995-09-19

  Compounds of formula (I): ##STR1## [wherein R.sup.1 represents a group of formula (II) or (III): ##STR2## R.sup.2 is alkyl, alkenyl or alkynyl; R.sup.3 and R.sup.4 are each hydrogen, alkyl, alkenyl or alkynyl; R.sup.5 is hydrogen or a carboxy-protecting group; R.sup.a is hydrogen or a group of formula and --OR.sup.6 ; R.sup.6, R.sup.6a and R.sup.6b are each hydrogen, a hydroxy-protecting group, alkyl, alkanesulfonyl, halogenated alkanesulfonyl or arylsulfonyl] and their salts and esters have the ability to inhibit the synthesis of cholesterol, and can thus be used for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.

  式(I)的化合物：##STR1## [其中R.sup.1代表式(II)或(III)的基团：##STR2## R.sup.2是烷基，烯基或炔基；R.sup.3和R.sup.4分别是氢，烷基，烯基或炔基；R.sup.5是氢或羧基保护基；R.sup.a是氢或式和--OR.sup.6的基团；R.sup.6，R.sup.6a和R.sup.6b分别是氢，羟基保护基，烷基，烷基磺酰，卤代烷基磺酰或芳基磺酰]及其盐和酯具有抑制胆固醇合成的能力，因此可用于治疗和预防高胆固醇血症和各种心脏疾病。
• Hexanhydronaphthalene ester derivatives, their preparation and their therapeutic uses
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0605230A1

  公开（公告）日：1994-07-06

  Compounds of formula (I): [wherein R1 represents a group of formula (II) or (III): R2 is alkyl, alkenyl or alkynyl ; R3 and R4 are each hydrogen, alkyl, alkenyl or alkynyl ; R5 is hydrogen or a carboxy-protecting group ; Ra is hydrogen or a group of formula and -OR6 ; R6, R6a and R6b are each hydrogen, a hydroxy-protecting group, alkyl, alkanesulphonyl, halogenated alkanesulphonyl or arylsulphonyl] and their salts and esters have the ability to inhibit the synthesis of cholesterol, and can thus be used for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.

  式(I)化合物： [其中 R1 代表式 (II) 或 (III) 的基团： R2 是烷基、烯基或炔基；R3 和 R4 分别是氢、烷基、烯基或炔基；R5 是氢或羧基保护基团；Ra 是氢或式和 -OR6 的基团；R6、R6a 和 R6b 分别为氢、羟基保护基团、烷基、烷磺酰基、卤代烷磺酰基或芳基磺酰基]及其盐和酯具有抑制胆固醇合成的能力，因此可用于治疗和预防高胆固醇血症和各种心脏疾病。
• Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0609058B1

  公开（公告）日：1998-12-09
• Process for obtaining HMG-CoA reductase inhibitors of high purity
  申请人：Grahek Rok

  公开号：US20070032549A1

  公开（公告）日：2007-02-08

  Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, Streptomyces, Actinomadura, Micromonospora, some are obtained by treating the fermentation products using the method of chemical synthesis or they are the products of total chemical synthesis. The purity of the active ingredient is an important factor for manufacturing the safe and effective pharmaceutical, especially if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment. The present invention relates to a new industrial process for the isolation of HMG-CoA reductase inhibitors using so-called displacement chromatography. Use of the invention enables one to obtain HMG-CoA reductase inhibitors of high purity, with high yields, lower production costs and suitable ecological balance.
• US5451688A
  申请人：——

  公开号：US5451688A

  公开（公告）日：1995-09-19